Members of the investor and media communities will find a number of tools and resources below. Please click on the respective links to access our investor toolbox or the media center.
Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company committed to developing medicines to meet the needs of patients living with mitochondrial and other rare diseases.
Our focus is on the development of treatments for neuromuscular and neuro-ophthalmological diseases that currently lack treatment options, such as Leber’s hereditary optic neuropathy (LHON), Duchenne muscular dystrophy (DMD), Congenital muscular dystrophy (CMD) and primary progressive multiple sclerosis (PPMS).
Since 2004, we have developed our pipeline by conducting numerous clinical studies in Europe and North America. In September 2015, we received European Marketing Authorization for Raxone to treat patients with LHON, making Raxone the first and only treatment to be approved for treatment of this condition and the first to be approved for any mitochondrial disorder: a major milestone in addressing the unmet medical need represented by this group of rare diseases.
Our clinical program for Raxone continues in the areas of DMD and PPMS. We are also actively investigating omigapil (an investigational drug with anti-apoptotic properties) in congenital muscular dystrophy (CMD).